Industry Focus

Carl Icahn's reportedly focusing his brand of investor activism on Bristol-Myers Squibb, but it's anyone's guess if he'll be able to convince the company to sell. Also, Celgene delivers a phase 3 win with blockbuster implications.

Direct download: 20170222_IF_Healthcare.mp3
Category:Podcast -- posted at: 3:30pm EDT